Trials / Completed
CompletedNCT04161781
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
Pilot Trial of 18F-BMS-986229 PET in Esophagogastric Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to test 18F-BMS-986229 positron emission tomography (PET) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.
Conditions
- Esophagogastric Cancer
- Esophagus Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-BMS-986229 Injection | Single injection prior to scan |
| DRUG | IV 18F-BMS-986229 | 370 MBq administered intravenously prior to scan |
| DIAGNOSTIC_TEST | PET/CT Scan | Whole-body PET/CT (80 mA) |
Timeline
- Start date
- 2019-11-12
- Primary completion
- 2024-03-06
- Completion
- 2024-03-06
- First posted
- 2019-11-13
- Last updated
- 2025-05-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04161781. Inclusion in this directory is not an endorsement.